Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 10/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14010494 | 1.00 | SLC29A1 (0.56) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL5006171 | 1.00 | SLC29A1 (0.56) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL5006174 | 1.00 | SLC29A1 (0.56) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL14036337 | 0.94 | SLC29A1 (0.54) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL8291855 | 0.94 | SLC29A1 (0.54) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL5007176 | 0.94 | SLC29A1 (0.54) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL8291841 | 0.94 | SLC29A1 (0.54) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL14010256 | 0.94 | SLC29A1 (0.54) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL14010240 | 0.94 | SLC29A1 (0.54) | SLC29A1HPGDSLMNAGRIN2BKCNH2 | |
| SCHEMBL8291852 | 0.94 | SLC29A1 (0.54) | SLC29A1HPGDSLMNAGRIN2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452893-B2 | 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452893-B2 | 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | MERCK & CO., INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | MERCK & CO., INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | GRIN2B, GRIN3A, GRIN2A | SLC29A1 1946/4885HPGDS 560/4885LMNA 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.